Clinical benefits of pegylated proteins in oncology-Reference-Cited by-同舟云学术

Clinical benefits of pegylated proteins in oncology

Published:2002-01 Issue: Volume:28 Page:1-2
ISSN:0305-7372
Container-title:Cancer Treatment Reviews
language:en
Short-container-title:Cancer Treatment Reviews

Author:

Crawford J.

Publisher

Elsevier BV

Subject

Radiology, Nuclear Medicine and imaging,Oncology,General Medicine

Reference7 articles.

1. Controlled-release, pegylation, liposomal formulations: new mechanisms in the delivery of injectable drugs;Reddy;Ann Pharmacother,2000

2. Polyethylene glycol conjugated pharmaceutical proteins;Bailon;Pharm Sci Technol Today,1998

3. Randomized, dose-escalation study of SD/01 compared with daily filgrastim in patients receiving chemotherapy;Johnston;J. Clin Oncol,2000

4. Phase II trial of branched pegylated (40kDa) interferon α-2a for patients with advanced renal cell carcinoma (RCC) [abstract 716];Motzer;Proc Am Soc Clin Oncol,2001

5. Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group;Judson;Eur J Cancer,2001

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Optimizing early phase clinical trial washout periods: a report from the Therapeutic Advances in Childhood Leukemia and Lymphoma consortium;JNCI: Journal of the National Cancer Institute;2024-07-04

2. Therapeutic targeting of TRAIL death receptors;Biochemical Society Transactions;2023-01-11

3. Journey of Poly(ethylene Glycol) in Living Cells;ACS Applied Materials & Interfaces;2021-08-23

4. Ultrasound for the treatment of acute kidney injury and other inflammatory conditions: a promising path toward noninvasive neuroimmune regulation;American Journal of Physiology-Renal Physiology;2020-07-01

5. Nanocarriers for TRAIL delivery: driving TRAIL back on track for cancer therapy;Nanoscale;2017